Parathyroid Disorders

Disease State Hub

FDA Alerts

FDA

FDA Approves New Option for Hyperparathyroidism

02/08/2017

The FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.

02/08/2017

Research Summaries

Research Summary

Parathyroidectomy Has No Effect on Preserving Kidney Function in Older Adults With Hyperparathyroidism

06/14/2023

Jessica Ganga

Researchers evaluated the effectiveness of parathyroidectomy to manage kidney function in adults with hyperparathyroidism.

06/14/2023

bone density

Disrupting sleep and circadian rhythms alters bone metabolism

08/09/2017

Circadian disruption and sleep restriction could lead to bone loss over time, with particularly strong effects in younger men, new research shows.

08/09/2017

FDA

FDA Approves New Option for Hyperparathyroidism

02/08/2017

The FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.

02/08/2017

April 2024

Current Issue

April 2024

Volume 64

Issue 4